Shingrix Vaccine Demand Creates Shortages

November 6, 2018



Unprecedented adoption of the Shingrix vaccine has created limited supplies which are expected to continue throughout the remainder of 2018. At MSU pharmacy, our first priority is patient safety. To help ensure patients who have started the two-dose Shingrix vaccination can complete it, we will prioritize our stock of Shingrix for patients who require the second dose until the backorder status is resolved.

The Shingrix vaccine has created limited supplies around the country starting as of June 2018. In September, we were notified by GSK, the maker of Shingrix to expect the backorder and limited dose schedule to continue throughout the remainder of 2018.

The scheduled supply has kept pace with demand of the vaccination at the MSU Clinical Center Pharmacy through October.

“We usually see an increase for the shingles vaccine at this time of year,” informed Sandra Campbell, PharmD, Chief Pharmacist for MSU HealthTeam Pharmacies. Regarding the change in managing the limited supply of Shingrix. “It’s time to make sure we can fulfill our commitment to patients who received their first dose of Shingrix.” she continued.


About Shingrix

The CDC recommends healthy adults aged 50 years and older receive two doses of the shingles vaccine separated by 2 to 6 months. Shingrix is more than 90% effective at preventing Shingles and its most common complication, postherpetic neuralgia (PHN) when both doses are administered. People who have medical conditions that keep the immune system from working properly, or people who receive immunosuppressive drugs are also at greater risk to get shingles.

To learn more about the shingles virus and Shingrix as the preferred vaccine from the CDC visit